-$0.25 EPS Expected for Kadmon Co. (KDMN) This Quarter

Analysts expect Kadmon Co. (NYSE:KDMN) to report earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Kadmon’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.23). Kadmon reported earnings per share of ($0.39) in the same quarter last year, which would indicate a positive year-over-year growth rate of 35.9%. The business is expected to report its next quarterly earnings results on Monday, May 21st.

According to Zacks, analysts expect that Kadmon will report full-year earnings of ($1.11) per share for the current year, with EPS estimates ranging from ($1.25) to ($0.96). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.29) to ($0.38). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Kadmon.

How to Become a New Pot Stock Millionaire

Kadmon (NYSE:KDMN) last released its earnings results on Tuesday, March 6th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.12. The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $3.07 million. During the same period in the prior year, the business earned ($0.50) EPS. The company’s quarterly revenue was down 65.1% on a year-over-year basis.



KDMN has been the topic of a number of research analyst reports. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Friday, January 12th. Jefferies Group increased their target price on Kadmon to $16.00 and gave the stock a “buy” rating in a report on Tuesday, February 13th. Piper Jaffray reaffirmed a “positive” rating and set a $9.00 target price (up previously from $7.00) on shares of Kadmon in a report on Tuesday, February 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Kadmon in a report on Friday, March 9th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Kadmon currently has an average rating of “Hold” and a consensus target price of $11.45.

NYSE:KDMN opened at $3.98 on Friday. Kadmon has a 52 week low of $2.05 and a 52 week high of $5.86.

Several institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN raised its position in shares of Kadmon by 23.2% during the 3rd quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock worth $247,000 after purchasing an additional 13,923 shares during the period. Bank of New York Mellon Corp raised its position in shares of Kadmon by 66.6% during the 4th quarter. Bank of New York Mellon Corp now owns 59,430 shares of the company’s stock worth $216,000 after purchasing an additional 23,763 shares during the period. BlueCrest Capital Management Ltd acquired a new stake in shares of Kadmon during the 4th quarter worth approximately $241,000. BlackRock Inc. raised its position in shares of Kadmon by 151.2% during the 4th quarter. BlackRock Inc. now owns 208,190 shares of the company’s stock worth $754,000 after purchasing an additional 125,308 shares during the period. Finally, AE Wealth Management LLC raised its position in shares of Kadmon by 61.1% during the 4th quarter. AE Wealth Management LLC now owns 520,713 shares of the company’s stock worth $1,885,000 after purchasing an additional 197,552 shares during the period. Institutional investors and hedge funds own 61.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/04/25/0-25-eps-expected-for-kadmon-co-kdmn-this-quarter.html.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases.

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply